JP2004501101A - Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置 - Google Patents

Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置 Download PDF

Info

Publication number
JP2004501101A
JP2004501101A JP2001583803A JP2001583803A JP2004501101A JP 2004501101 A JP2004501101 A JP 2004501101A JP 2001583803 A JP2001583803 A JP 2001583803A JP 2001583803 A JP2001583803 A JP 2001583803A JP 2004501101 A JP2004501101 A JP 2004501101A
Authority
JP
Japan
Prior art keywords
variant
dose
antibody
her2
her2 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001583803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501101A5 (cg-RX-API-DMAC7.html
Inventor
カリギウリ，　マイケル　エイ．
メロポル，　ニール　ジェイ．
シルスカイ，　リチャード　エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of JP2004501101A publication Critical patent/JP2004501101A/ja
Publication of JP2004501101A5 publication Critical patent/JP2004501101A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2001583803A 2000-05-15 2001-05-15 Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置 Pending JP2004501101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20428400P 2000-05-15 2000-05-15
US09/855,342 US7306801B2 (en) 2000-05-15 2001-05-14 Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
PCT/US2001/015525 WO2001087336A1 (en) 2000-05-15 2001-05-15 Cancer treatments by using a combination of an antibody against her2 and interleukin -2

Publications (2)

Publication Number Publication Date
JP2004501101A true JP2004501101A (ja) 2004-01-15
JP2004501101A5 JP2004501101A5 (cg-RX-API-DMAC7.html) 2008-07-03

Family

ID=26899337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001583803A Pending JP2004501101A (ja) 2000-05-15 2001-05-15 Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置

Country Status (7)

Country Link
US (2) US7306801B2 (cg-RX-API-DMAC7.html)
EP (1) EP1282442A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004501101A (cg-RX-API-DMAC7.html)
AU (1) AU2001261569A1 (cg-RX-API-DMAC7.html)
CA (1) CA2408974A1 (cg-RX-API-DMAC7.html)
IL (1) IL152896A0 (cg-RX-API-DMAC7.html)
WO (1) WO2001087336A1 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2436595C (en) * 2000-12-08 2011-11-08 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
EP1569689A4 (en) * 2002-01-18 2009-08-05 Novartis Vaccines & Diagnostic IL2 / ANTI-HER2-ANTIBODY COMBINATION THERAPY AGAINST CANCER, which is characterized by overexpression of the HER2-RECEPTOR PROTEIN
DK1531850T3 (da) * 2002-06-07 2012-06-04 Zymogenetics Inc Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
US7632496B2 (en) 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
BRPI0511187A (pt) * 2004-05-20 2007-12-04 Zymogenetics Inc método para tratar cáncer em um indivìduo
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1850874B1 (en) * 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US8105768B2 (en) 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
EP1942937A1 (en) * 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US20070111906A1 (en) * 2005-11-12 2007-05-17 Milner Jeffrey L Relatively low viscosity transmission fluids
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US8350011B2 (en) * 2006-08-04 2013-01-08 Medimmune Limited Antibodies to ErbB2
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
PL2171090T3 (pl) * 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
AU2008279618B2 (en) * 2007-07-25 2014-05-22 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010051502A2 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
KR20130036192A (ko) 2010-02-11 2013-04-11 알렉시온 파마슈티칼스, 인코포레이티드 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
KR101453462B1 (ko) * 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
US9586056B2 (en) 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
WO2016052971A1 (ko) * 2014-09-30 2016-04-07 가톨릭대학교 산학협력단 유방암 진단용 허셉틴-광감각제 접합체 및 이의 제조 방법
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
EP3368092B9 (en) 2015-10-29 2020-07-29 Novartis AG Antibody conjugates comprising toll-like receptor agonist
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360942A (ja) * 1986-08-01 1988-03-17 シタス　コ−ポレイシヨン インタ−ロイキン−２と共に免疫毒素又は抗体を用いてのコンビネ−ション治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
EP1569689A4 (en) * 2002-01-18 2009-08-05 Novartis Vaccines & Diagnostic IL2 / ANTI-HER2-ANTIBODY COMBINATION THERAPY AGAINST CANCER, which is characterized by overexpression of the HER2-RECEPTOR PROTEIN

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360942A (ja) * 1986-08-01 1988-03-17 シタス　コ−ポレイシヨン インタ−ロイキン−２と共に免疫毒素又は抗体を用いてのコンビネ−ション治療

Also Published As

Publication number Publication date
US20020031515A1 (en) 2002-03-14
US20080159981A1 (en) 2008-07-03
IL152896A0 (en) 2003-06-24
AU2001261569A1 (en) 2001-11-26
US7306801B2 (en) 2007-12-11
WO2001087336A1 (en) 2001-11-22
EP1282442A1 (en) 2003-02-12
CA2408974A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
US7306801B2 (en) Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
KR102624564B1 (ko) 항-ctla4 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-ctla4 항체의 안정한 제제 및 그의 사용 방법
EP2056874B1 (en) Tumor therapy with an anti-vegf antibody
JP7579705B2 (ja) アンタゴニスト抗ｐｄ－１抗体による癌の治療方法
US20020009427A1 (en) Methods of therapy for non-hodgkin's lymphoma
KR100909290B1 (ko) 항암 항체
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
JP7459058B2 (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
JP7448552B2 (ja) がんの併用療法
TWI767139B (zh) 抗ｈｅｒ２抗體藥物偶聯物在治療尿路上皮癌中的用途
KR20080110987A (ko) 항-ｅｇｆｒ 및 항-ｈｅｒ２ 항체를 이용하는 조합 요법
JP2005538034A (ja) 非ホジキンリンパ腫の治療方法
US20240199758A1 (en) Method for allowing immune cells infiltration in tumors
JP2021523096A (ja) 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画
CN118373896B (zh) 抗pd-1抗体与il-2突变体的双功能融合蛋白
US20030235556A1 (en) Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
KR20250029883A (ko) 조합 요법
EP1935431A2 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
IL293626A (en) Treatment with site specific her2 antibody-drug conjugates
CN120204383A (zh) 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
KR20250148463A (ko) 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체
CN121622921A (zh) Her2 adc药物组合物及其用途
HK40128545A (zh) 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
HK40035107A (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110808